Top current, economic, financial, and business news moving the markets.
General Mills (GIS) reported its fiscal 2026 third-quarter results today, March 18, 2026, showing net sales of $4.4 billion (an 8% decline) and an adjusted EPS of $0.64 (a 37% drop). Despite severe margin contraction driven by “remarkability” investments and strategic divestitures (Yogurt and Brazil), the company reaffirmed its full-year guidance. With the stock sliding […]
As of March 2026, the US Dollar has reaffirmed its global hegemony, hitting price levels not seen since May 2025. Contrary to “de-dollarization” narratives, the DXY index exhibits superior technical resilience, backed by a global flight to safety and the unparalleled depth of US capital markets. Current data suggests a continued bullish trajectory, driven by
In March 2026, the U.S. Financial Sector faces a systemic liquidity crisis in the $2 trillion private credit market. With default rates hitting 9.2% and giants like Blackstone and Morgan Stanley gating redemptions, the scenario mirrors 2008. AI disruption in the software sector has devalued critical collateral, forcing asset sales at discounts up to 35%.
In March 2026, escalating US-Iran tensions have pushed the VIX to the 23-point range, signaling heightened caution but not outright panic. Technical analysis identifies Brent crude above $80 as the primary inflationary trigger monitored by the Fed. Historically, geopolitical shocks result in a median +3% return over 12 months. The current strategy focuses on diplomatic
NVIDIA’s Q4 FY26 results confirm its absolute leadership in AI infrastructure, posting record revenue of $68.1 billion (+73% YoY) and net income of $43 billion. Despite a forward P/E of 18 for 2027, which appears to be a historic discount relative to growth, the absence of revenue from China and the potential cyclicality of software
Novo Nordisk (NVO) shares plummeted over 21% in 48 hours following REDEFINE 4 trial data, where CagriSema showed a 23% weight loss compared to Eli Lilly’s Zepbound at 25.5%. Despite the market’s knee-jerk reaction, fundamental analysis reveals a 2026 P/E of 11x, a massive discount compared to Lilly’s 30x. With a robust pipeline including oral
